Dianthus Therapeutics
DNTH
84.55
-0.28
-0.33%
Dianthus Therapeutics
US · DNTH
#2155 by market cap
Listed 1970
84.55
-0.28
-0.33%
Periodic snapshot; not a real-time feed.
· 2026-11-20 19:59
Recent news
-
Dianthus Therapeutics(DNTH.US) Officer Sells US$11.23 Million in Common StockMarket Newswire · 2026/11/13
-
Rating change
Roth MKM Maintains Dianthus Therapeutics(DNTH.US) With Buy Rating, Maintains Target Price $113Market Newswire · 2026/10/27
-
Rating change
Jefferies Maintains Dianthus Therapeutics(DNTH.US) With Buy Rating, Maintains Target Price $132Market Newswire · 2026/6/15
-
Rating change
A Quick Look at Today's Ratings for Dianthus Therapeutics(DNTH.US), With a Forecast Between $122 to $150Market Newswire · 2026/8/5
-
Rating change
Raymond James Maintains Dianthus Therapeutics(DNTH.US) With Buy RatingMarket Newswire · 2026/6/13
-
Rating change
J.P. Morgan Initiates Dianthus Therapeutics(DNTH.US) With Buy Rating, Announces Target Price $135Market Newswire · 2026/9/11
-
H.C. Wainwright Maintains Dianthus Therapeutics(DNTH.US) With Buy Rating, Maintains Target Price $158Market Newswire · 2026/11/7
-
Rating change
Truist Financial Maintains Dianthus Therapeutics(DNTH.US) With Buy RatingMarket Newswire · 2026/6/15
-
Wells Fargo Maintains Dianthus Therapeutics(DNTH.US) With Buy Rating, Maintains Target Price $135Market Newswire · 2026/11/5
-
Rating change
Wedbush Maintains Dianthus Therapeutics(DNTH.US) With Buy Rating, Maintains Target Price $105Market Newswire · 2026/6/15
-
A Quick Look at Today's Ratings for Dianthus Therapeutics(DNTH.US), With a Forecast Between $122 to $135Market Newswire · 2026/11/6
-
Rating change
Evercore Maintains Dianthus Therapeutics(DNTH.US) With Buy Rating, Raises Target Price to $134Market Newswire · 2026/8/10
-
Rating change
Citi Initiates Dianthus Therapeutics(DNTH.US) With Buy Rating, Announces Target Price $156Market Newswire · 2026/9/4
-
Rating change
William Blair Maintains Dianthus Therapeutics(DNTH.US) With Buy RatingMarket Newswire · 2026/9/18
-
Rating change
A Quick Look at Today's Ratings for Dianthus Therapeutics(DNTH.US), With a Forecast Between $122 to $200Market Newswire · 2026/8/6
-
Rating change
J.P. Morgan Maintains Dianthus Therapeutics(DNTH.US) With Buy RatingMarket Newswire · 2026/9/24
-
Rating change
Truist Financial Maintains Dianthus Therapeutics(DNTH.US) With Buy Rating, Announces Target Price $128Market Newswire · 2026/8/6
-
Rating change
Roth MKM Initiates Dianthus Therapeutics(DNTH.US) With Buy Rating, Announces Target Price $113Market Newswire · 2026/10/27
-
Rating change
LifeSci Capital Maintains Dianthus Therapeutics(DNTH.US) With Buy Rating, Maintains Target Price $125Market Newswire · 2026/9/30
-
Stifel Maintains Dianthus Therapeutics(DNTH.US) With Buy Rating, Maintains Target Price $133Market Newswire · 2026/11/13
-
Rating change
H.C. Wainwright Maintains Dianthus Therapeutics(DNTH.US) With Buy Rating, Maintains Target Price $130Market Newswire · 2026/6/12
-
Rating change
Stifel Maintains Dianthus Therapeutics(DNTH.US) With Buy Rating, Maintains Target Price $133Market Newswire · 2026/8/14
-
Rating change
Wells Fargo Maintains Dianthus Therapeutics(DNTH.US) With Buy Rating, Maintains Target Price $135Market Newswire · 2026/6/17
-
Rating change
Wedbush Maintains Dianthus Therapeutics(DNTH.US) With Buy Rating, Raises Target Price to $105Market Newswire · 2026/6/12
-
H.C. Wainwright Maintains Dianthus Therapeutics(DNTH.US) With Buy Rating, Maintains Target Price $158Market Newswire · 2026/10/16
Headlines are aggregated automatically and are not independently verified or edited by our team.
Quote time 2026-11-20 19:59:44 · For reference only, not investment advice and not tailored to your situation.
Dianthus Therapeutics discussion 0 comments